In March 2025, I wrote about an organelle most people have never heard of — the peroxisome — and how COVID destroys it in lung macrophages, locking in chronic inflammation and fibrosis. That post was built on Sun et al. in Science, from the University of Virginia. The finding was striking: an FDA-approved drug called sodium phenylbutyrate (NaPB) could restore peroxisome function and reverse the damage in mice.
One question lingered. If this organelle breaks in the lungs, does it break elsewhere?
The answer arrived twelve months later from the other side of the world.
The Sequel From Wuhan
Wang et al., published in Developmental Cell in March 2026, reports findings from Wuhan University and West China Hospital of Sichuan University. The team surveyed 1,032 healthcare workers who survived COVID-19 infection and found persistent gastrointestinal symptoms — diarrhea, inflammation, microbiota dysbiosis — driven by the same organelle failure.
The mechanism mirrors the lung story almost exactly, but the cell type is different. In the lungs, peroxisomes fail in macrophages. In the gut, they fail in intestinal stem cells. The consequence is the same: the tissue cannot repair itself.
Here is the parallel, side by side.
Two continents. Two cell types. One organelle. And both teams, working independently, converged on the same class of FDA-approved drugs.
How the Gut Pathway Works
Wang et al. traced a specific cascade. SARS-CoV-2 establishes persistent reservoirs in intestinal tissue — a finding now supported by multiple groups, including gut biopsy studies showing viral RNA months after acute infection. These reservoirs disrupt the metabolism of very-long-chain fatty acids (VLCFAs), which are lipids with carbon chains of 22 atoms or more.
Under normal conditions, peroxisomes break down VLCFAs through a process called β-oxidation. When peroxisome function is suppressed, VLCFAs accumulate. The accumulation suppresses PPAR signaling — the nuclear receptor pathway that, among other things, drives peroxisome biogenesis. This creates a self-reinforcing loop: fewer peroxisomes means more VLCFA accumulation, which means even fewer peroxisomes.
In the gut, the downstream target is intestinal stem cells. These cells are responsible for regenerating the intestinal epithelium — the single-cell-thick barrier that separates the contents of the gut from the bloodstream. When stem cell differentiation fails, the epithelium cannot repair itself. The result is chronic inflammation, persistent diarrhea, and microbial dysbiosis as the gut barrier degrades.
The VLCFA Bridge to Monocytes
This is where the peroxisome story connects to the larger arc I've been building since Post #19.
When peroxisomes fail and VLCFAs accumulate, the excess fatty acids don't just impair local stem cells. A 2022 study in the Journal of Neuroinflammation demonstrated that saturated VLCFAs prime macrophage membranes for persistent inflammation. The mechanism involves the c-Jun N-terminal kinase (JNK) pathway: VLCFAs activate JNK signaling, which drives pro-inflammatory chemokine release and increases macrophage invasiveness.
Critically, the study showed that ABCD1-mediated peroxisomal β-oxidation of VLCFAs resolves this inflammatory state. When peroxisomes work, macrophages clear VLCFAs and return to baseline. When peroxisomes fail, macrophages stay primed.
This provides a metabolic explanation for a question I raised in my coverage of the bone marrow reprogramming arc: why do LC-Mo monocytes remain locked in a pro-inflammatory state? The Kumar et al. findings in Nature Immunology identified the epigenetic lock. But the metabolic fuel — the thing keeping the fire lit — may be VLCFA accumulation from failed peroxisomal clearance.
The connection: Bone marrow reprogramming (Post #19) creates inflammatory monocytes. Peroxisome failure locks them in that state metabolically. The epigenetic program is the blueprint; the VLCFA accumulation is the fuel.
Two Drugs, Two Price Tags
Both studies converge on the same therapeutic strategy: restore peroxisome function. But the drugs available to do this come from very different economic realities.
| Drug | Mechanism | Organ Evidence | Approx. Monthly Cost | Status |
|---|---|---|---|---|
| Sodium phenylbutyrate (NaPB) | Peroxisome biogenesis — directly increases peroxisome abundance | Lungs + Gut | $2,200–$14,000+ | FDA-approved (urea cycle disorders). No LC trial registered. |
| Fenofibrate | PPAR-α agonist — activates peroxisome proliferation via receptor signaling | Gut only | $10–$15 (generic) | FDA-approved (cholesterol). Failed in acute COVID (701 pts). No LC trial registered. |
The price gap is enormous. NaPB is a specialty drug for rare urea cycle disorders, with branded formulations running thousands per month. Fenofibrate is a 50-year-old generic cholesterol medication available at any pharmacy for under $15 with a discount card.
Wang et al. tested both. Both restored peroxisome function in their gut models. But fenofibrate works through a different pathway — it activates PPAR-α receptors, which then drive peroxisome proliferation, rather than directly stimulating peroxisome biogenesis the way NaPB does. Whether this difference matters clinically — whether one approach is more durable or effective than the other — is unknown.
The Critical Caveat
Fenofibrate has already been tested in acute COVID-19 and failed. A 701-patient randomized trial published in Nature Metabolism found no benefit for disease severity or mortality. But this was the wrong question asked at the wrong time. Acute COVID-19 is a viral replication problem. The peroxisome failure that Wang and Sun describe is a post-acute repair problem — a different biological phase entirely.
The analogy: testing a wound-healing drug during the injury itself, then declaring it doesn't work when the wound won't close months later. Timing matters. I made a similar argument about metformin in Post #4, and the principle applies here: drugs that fail in the acute window may succeed in the post-acute repair window, because they're targeting different biology.
That said, no clinical trial has been registered testing either NaPB or fenofibrate specifically in Long COVID patients. As of April 2026, this remains preclinical evidence — animal models, Drosophila, human tissue samples, and a cohort survey. It is not a treatment recommendation. It is a research finding with therapeutic potential that needs human trials.
What This Changes
The peroxisome is emerging as a convergence point for Long COVID pathology across organs. The evidence now spans:
- • Lungs — macrophage peroxisome failure → blocked alveolar repair → fibrosis (Sun et al., Science 2025)
- • Gut — stem cell peroxisome failure → blocked epithelial regeneration → chronic GI symptoms (Wang et al., Dev Cell 2026)
- • Immune system — VLCFA accumulation from peroxisome failure primes macrophages for persistent inflammation via JNK (Demmings et al., J Neuroinflammation 2022)
- • Energy metabolism — peroxisomes cooperate with mitochondria in fatty acid β-oxidation; failure in one stresses the other (Post #3)
This is not yet a complete theory. But it is a pattern. An organelle that most biology textbooks relegate to a footnote is now implicated in at least four dimensions of Long COVID pathology, with two independent groups showing that FDA-approved drugs can restore its function in preclinical models.
What's needed next is straightforward: a clinical trial testing fenofibrate — the $10/month generic — in Long COVID patients with persistent GI symptoms. The preclinical evidence is there. The drug has 50 years of safety data. The barrier is not science. It's someone deciding to run the trial.
Sources: Wang et al., Developmental Cell 61(3):571-588 (2026). Sun et al., Science (2025). Demmings et al., J Neuroinflammation (2022). Lowe et al., Nature Metabolism (2022). This post connects to Posts #3, #12, #19, #20, #21, and #26.